Drug Description in Trials / DrugBank / KEGG DRUG
Search results
Showing 1 to 10 of 632 descriptions
| No. | Drug (Description in trials) | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | Disease ID | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (-)-Epicatechin | [1] Epicatechin Epicatechin | - | - | - | [2] 86 86, 113 💬
| ||||||||||||
| 2 | (18F)FPGLU | - | - | - | - | [1] 86 86 💬2. (18F)FPGLU
| ||||||||||||
| 3 | (Pyr1)apelin-13 | - | - | - | - | [1] 86 86 💬3. (Pyr1)apelin-13
| ||||||||||||
| 4 | (S)-2-(4,6-dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropanoic acid | - | - | - | - | [1] 86 86 💬4. (S)-2-(4,6-dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropanoic acid
| ||||||||||||
| 5 | (S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2- YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM (S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2- YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-I ... | - | - | - | - | [1] 86 86 💬5. (S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2- YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM
| ||||||||||||
| 6 | (S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2-YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM (S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2-YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IU ... | - | - | - | - | [1] 86 86 💬6. (S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2-YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM
| ||||||||||||
| 7 | **Comment**- IMP inhalation solution identical to ventavis inhalation solution, but IMP is in a different volume presentation. Please see covering letter. **Comment**- IMP inhalation solution identical to ventavis inhalation solution, but IMP is in a diff ... | [1] Iloprost Iloprost | [1] Iloprost
Iloprost
💬7. **Comment**- IMP inhalation solution identical to ventavis inhalation solution, but IMP is in a different volume presentation. Please see covering letter.
| [1] PTGIR PTGIR 💬7. **Comment**- IMP inhalation solution identical to ventavis inhalation solution, but IMP is in a different volume presentation. Please see covering letter.
| [3] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 [3] Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction ... | [1] 86 86 💬7. **Comment**- IMP inhalation solution identical to ventavis inhalation solution, but IMP is in a different volume presentation. Please see covering letter.
| ||||||||||||
| 8 | 10-nitro-9(E)-octadec-9-enoic acid | - | - | - | - | [1] 86 86 💬8. 10-nitro-9(E)-octadec-9-enoic acid
| ||||||||||||
| 9 | 11C-ACETATE | [2] Acetate Acetate,Acetic acid C-11 | - | - | - | [4] 6 6, 13, 86, 88 💬
| ||||||||||||
| 10 | 120 mg sodium nitrite inhalation solution | [1] Nitrite Nitrite | - | - | - | [1] 86 86 💬10. 120 mg sodium nitrite inhalation solution
|